Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

被引:123
|
作者
Koo, HM
VanBrocklin, M
McWilliams, MJ
Leppla, SH
Duesbery, NS
Vande Woude, GF
机构
[1] Van Andel Res Inst, Grand Rapids, MI 49503 USA
[2] Natl Canc Inst, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, Ft Detrick, MD 21702 USA
[3] Natl Inst Dental Res, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1073/pnas.052707699
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lethal factor, the principal virulence factor of Bacillus anthracis, inhibits mitogen-activated protein kinase (MAPK) signaling by proteolytically cleaving MAPK kinases. Edema factor, another component of anthrax toxin, is an adenylate cyclase, which increases intracellular cAMP. Inhibition of MAPK signaling with either anthrax lethal toxin (LeTx) or small molecule MAPK kinase inhibitors triggers apoptosis in human melanoma cells. Normal melanocytes do not undergo apoptosis in response to MAPK inhibition but arrest in the G, phase of the cell cycle. importantly, in vivo treatment of human melanoma xenograft tumors in athymic nude mice with LeTx results in significant or complete tumor regression without apparent side effects, suggesting that inhibiting the MAPK signaling pathway may be a useful strategy for treating melanoma. Additionally, interrupting MAPK signaling with LeTx and elevating cAMP with anthrax edema toxin in both melanoma cells and melanocytes lead to dramatic melanin production, perhaps explaining the formation of blackened eschars in cutaneous anthrax.
引用
收藏
页码:3052 / 3057
页数:6
相关论文
共 50 条
  • [1] Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase
    Duesbery, NS
    Vande Woude, GF
    JOURNAL OF APPLIED MICROBIOLOGY, 1999, 87 (02) : 289 - 293
  • [2] Anthrax lethal factor causes proteolytic inactivation of mitogen- activated protein kinase kinase
    ABL-Basic Research Program, Division of Basic Sciences, NCI-FCRDC, Frederick, MD, United States
    不详
    不详
    不详
    J. Appl. Microbiol., 2 (289-293):
  • [3] Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor
    Vitale, G
    Bernardi, L
    Napolitani, G
    Mock, M
    Montecucco, C
    BIOCHEMICAL JOURNAL, 2000, 352 : 739 - 745
  • [5] Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades
    Chan-Hui, PY
    Weaver, R
    BIOCHEMICAL JOURNAL, 1998, 336 : 599 - 609
  • [6] Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes
    Shakibaei, M
    Schulze-Tanzil, G
    de Souza, P
    John, T
    Rahmanzadeh, M
    Rahmanzadeh, R
    Merker, HJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) : 13289 - 13294
  • [7] Apoptosis induced by pneumolysin in human endothelial cells involves mitogen-activated protein kinase phosphorylation
    Zhou, Aie
    Wang, Hong
    Lan, Kai
    Zhang, Xuemei
    Xu, Wenchun
    Yin, Yibing
    Li, Dairong
    Yuan, Jun
    He, Yujuan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 29 (06) : 1025 - 1030
  • [8] Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway
    Yu, CR
    Wang, SJ
    Dent, P
    Grant, S
    MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 143 - 154
  • [9] Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma
    Alsina, J
    Gorski, DH
    Germino, FJ
    Shih, WC
    Lu, SE
    Zhang, ZG
    Yang, JM
    Hait, WN
    Goydos, JS
    CLINICAL CANCER RESEARCH, 2003, 9 (17) : 6419 - 6425
  • [10] BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin
    Abi-Habib, RJ
    Urieto, JO
    Liu, SH
    Leppla, SH
    Duesbery, NS
    Frankel, AE
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) : 1303 - 1310